TCG's investment strategy runs counter to the prevailing trend in life sciences venture capital toward assembling diversified portfolios of later stage, single product - orientated companies across multiple industry sectors, with proximity to value inflection points and the early identification of a Pharma «buyer» as key investment considerations. (thecolumngroup.com)